Press release
Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030, claims Roots Analysis
Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providersRoots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.”
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.
A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.
Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).
An analysis of the partnerships that have been established in this domain, in the recent past.
An analysis of the various expansion initiatives undertaken by the players in this domain.
An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.
A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.
A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.
A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Product
HPAPIs
Highly Potent Finished Dosage Forms
Company Size
Small-sized
Mid-sized
Large / Very Large
Scale of Operation
Preclinical / Clinical
Commercial
Type of Pharmacological Molecule
Small Molecules
Biologics
Type of Highly Potent Finished Dosage Form
Injectables
Oral Solids
Creams
Others
Key geographical regions
North America
Europe
Asia Pacific
Rest of the World
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies:
Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals)
Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research)
Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
Roberto Margarita (Business Development Director, CordenPharma)
Allison Vavala (Senior Manager, Business Development, Helsinn)
Mark Wright (Site Head, Piramal Healthcare)
Javier E. Aznárez Araiz (Business Development Technician, Idifarma)
Key companies covered in the report
AbbVie Contract Manufacturing
CARBOGEN AMCIS
Catalent
Evonik
Formosa Laboratories
Intas
Lonza
MabPlex
Pfizer CentreOne
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
Other Recent Offerings
1. Antibody Contract Manufacturing Market, 2020 – 2030
2. Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030
3. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030, claims Roots Analysis here
News-ID: 2191213 • Views: …
More Releases from Roots Analysis

Microbial Fermentation CMO Market Set to Triple by 2035, Fueled by Biologics Boo …
The microbial fermentation contract manufacturing organization (CMO) market is on an exciting growth trajectory, projected to soar from USD 3.6 billion in 2024 to over USD 9.1 billion by 2035. This robust expansion, at a compound annual growth rate (CAGR) of 8.7%, reflects the rising demand for biologics and the increasing trend of outsourcing microbial fermentation processes to specialized CMOs, according to a comprehensive new report by Roots Analysis.
Why Microbial…

Peptide Synthesis Market Set to Double by 2035, Driven by Surge in Outsourcing a …
In a world where precision medicine is rapidly reshaping healthcare, the global peptide synthesis market is emerging as a quiet powerhouse. According to a comprehensive new report from Roots Analysis, the sector is poised to leap from a $2.8 billion valuation in 2024 to an impressive $5.1 billion by 2035, growing at a steady 5.5% compound annual growth rate (CAGR). This growth is fueled by a perfect storm of scientific…

Global Needles Market Set to Surpass $14.7 Billion by 2035, Fueled by Chronic Di …
In a world where chronic diseases like diabetes, cancer, and heart conditions are on the rise, the humble needle has become an unsung hero of modern medicine. According to a new report from Roots Analysis, the global needles market is poised for remarkable growth-projected to leap from $8.1 billion in 2025 to over $14.7 billion by 2035, growing at a steady 6.1% annual clip. This surge isn't just about numbers;…

ADC Contract Manufacturing Market Set to Soar, Reaching USD 6.8 Billion by 2035
In the fast-evolving world of biopharmaceuticals, the demand for precision and innovation has never been higher. Nowhere is this more evident than in the rapidly expanding market for Antibody-Drug Conjugate (ADC) contract manufacturing. According to a comprehensive new report from Roots Analysis, the global ADC contract manufacturing market is poised for remarkable growth-projected to surge from USD 1.79 billion in 2024 to over USD 6.8 billion by 2035, at a…
More Releases for HPAPI
HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding…
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production.
At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures.
Key highlights include:
Alternative HPAPI manufacturing technologies to…
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements.
Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other…
HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca
Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing.
Peter said:
“The…
The Latest Techniques in HPAPI Facility Design
Amongst the myriad of potential pitfalls for the Highly Potential Active Pharmaceutical Ingredients (HPAPI) industry there is a requirement for all parties involved to have a blueprint in place to ensure all containment procedures are followed correctly. Yet, there is also a need to ensure that operations are maintained at the highest standards. At SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients Conference these issues will be discussed along with…
HPAPI (High Potency Active Pharmaceutical Ingredients) Market Report 2018: Segme …
Global HPAPI (High Potency Active Pharmaceutical Ingredients) market research report provides company profile for Lonza, Novasep, Thermofisher Scientific, Alkermes, Cambrex, Dishman, Dr. Reddy’S and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report…